Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

Elevance Health, Inc. (ELV) Stock Analysis: Exploring a 7% Upside ...

AI-generated analysis

πŸ“ˆ Elevance Health trades at $388.50 with an average analyst target price of $415.81, suggesting a 7.03% upside potential.

πŸ’° The company reports a Forward P/E ratio of 13.28 and generates over $4.29 billion in free cash flow.

πŸ“Š Financial performance includes an EPS of $23.58, a Return on Equity of 12.09%, and modest revenue growth of 2.60%.

πŸ’΅ Shareholders receive a dividend yield of 1.77% supported by a conservative 29.03% payout ratio.

πŸ‘ Analyst sentiment is strongly bullish with 14 buy ratings and zero sell ratings recorded for the stock.

πŸ“‰ Technical analysis shows an RSI of 32.16 indicating oversold conditions and a positive MACD crossover suggesting momentum.

πŸ₯ The firm operates through three strategic segments: Health Benefits, CarelonRx, and Carelon Services.

πŸ›‘οΈ Elevance Health maintains a substantial market capitalization of $84.37 billion within the healthcare sector.

Bullish Signals
  • Analysts maintain an average target price of $415.81, which represents a 7% upside from the current trading price of $388.50.
  • The stock has received 14 buy ratings with no sell ratings, indicating strong institutional confidence in future performance.
  • Free cash flow exceeds $4.29 billion, providing ample liquidity for operations and potential shareholder returns.
  • Technical indicators show a positive MACD of 5.61 above the signal line, signaling current bullish momentum.
  • The Relative Strength Index (RSI) is at 32.16, suggesting the stock may be undervalued or approaching a rebound from oversold levels.
  • A Forward P/E ratio of 13.28 suggests an attractive valuation relative to anticipated future earnings growth.
Full Analysis
Elevance Health, Inc. (NYSE: ELV) is a major U.S. healthcare company with a market capitalization of $84.37 billion, trading at $388.50. Analysts project an average target price of $415.81, implying approximately 7% upside potential from current levels. The stock has experienced volatility within its 52-week range of $274.66 to $424.43. Financial metrics highlight a Forward P/E ratio of 13.28 and robust free cash flow exceeding $4.29 billion, supporting operations and shareholder returns. The company offers a dividend yield of 1.77% with a conservative payout ratio of 29.03%. Recent performance shows modest revenue growth of 2.60%, an EPS of $23.58, and a Return on Equity of 12.09%. Analyst sentiment is overwhelmingly positive, with 14 buy ratings and no sell ratings. Technical indicators suggest potential bullish momentum, as the Relative Strength Index (RSI) sits at 32.16 near oversold territory and the MACD line remains above the signal line. The company operates through diversified segments including Health Benefits, CarelonRx, and Carelon Services under brands like Anthem Blue Cross and Blue Shield.